Department of Obstetrics, Gynaecology and Oncological Gynaecology, Medical University of Silesia, Bytom, Poland.
Int J Gynecol Cancer. 2009 Dec;19(9):1516-20. doi: 10.1111/IGC.0b013e3181bf425b.
Heat shock proteins (Hsp) are highly expressed in many malignant human tumors, including tumors of the genital tract. One of the Hsps strongly associated with the process of cancerogenesis is Hsp27. The presence of Hsp27 and anti-Hsp27 in the sera of patients with ovarian carcinoma is still a new research field, and papers contain contradictory results. The aim of this work was to study the concentrations of anti-Hsp27 immunoglobulin G antibodies in the sera of women with ovarian cancer at different clinical stages and with different histopathological types of this cancer.
Serum samples from 158 patients with ovarian carcinoma and 80 healthy women were investigated. The concentrations of anti-Hsp27 antibodies were determined by the enzyme-linked immunosorbent assay technique.
The mean concentration of anti-Hsp27 antibodies in the patients with ovarian carcinoma was significantly higher than that in the control group. Analysis in relation to the stage of clinical progression showed that the less advanced the cancerogenesis process, the higher the concentration of the anti-Hsp27 antibodies is. The mean concentrations of the anti-Hsp27 antibodies in the patients with ovarian carcinoma were not significantly different in relation to the histological type of the cancer. The use of chemotherapy as a primary anticancer treatment in ovarian carcinoma did not cause a significant decrease in the concentration of anti-Hsp27 antibodies.
An immunological response to Hsp27 is increased in women with ovarian carcinoma. Although the diagnostic concentrations of anti-Hsp27 antibodies have not been precisely defined yet, we believe that this may be a helpful diagnostic parameter particularly to detect early stages of clinical advancement of the disease.
热休克蛋白（Hsp）在许多人类恶性肿瘤中高度表达，包括生殖道肿瘤。与癌症发生过程强烈相关的 Hsp 之一是 Hsp27。Hsp27 及其抗体制现在卵巢癌患者血清中的存在仍然是一个新的研究领域，相关文献的结果存在矛盾。本工作旨在研究不同临床分期和不同组织病理学类型的卵巢癌患者血清中抗 Hsp27 免疫球蛋白 G 抗体的浓度。
研究了 158 例卵巢癌患者和 80 例健康女性的血清样本。采用酶联免疫吸附试验技术测定抗 Hsp27 抗体的浓度。
卵巢癌患者血清中抗 Hsp27 抗体的平均浓度明显高于对照组。与临床进展阶段的分析表明，癌症发生过程越不先进，抗 Hsp27 抗体的浓度越高。卵巢癌患者血清中抗 Hsp27 抗体的平均浓度与癌症的组织学类型无关。在卵巢癌中使用化疗作为主要抗癌治疗并没有导致抗 Hsp27 抗体浓度显著下降。
卵巢癌患者对 Hsp27 的免疫反应增加。虽然抗 Hsp27 抗体的诊断浓度尚未精确定义，但我们认为这可能是一个有用的诊断参数，特别是用于检测疾病临床进展的早期阶段。
